Atty. Docket No.: 3564/1010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Sedivy et al.

Serial No.:

09/654,281

Filed:

September 1, 2000

Entitled:

Kinase Inhibitors and Methods of Use in

Screening Assays and Modulation of

Cell Proliferation and Growth

Examiner:

Group Art Unit:

MAY 0 8 2001

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

Kathleen M. Wiliams, Ph.D.

Name of Person Mailing Paper

Signature of Person Mailing Paper

BOX SEQUENCE Commissioner for Patents

Washington, D.C. 20231

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- 1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosure;
- 2. Copy of Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- Paper copy of Corrected Sequence Listing; 3.
- 4. Disk of Corrected Sequence Listing in computer readable form; and
- 5. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 3564/1010. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Name: Kathleen M. Williams, Ph.D.

Registration No.: 34,380 Palmer & Dodge LLP One Beacon Street

Boston, MA 02108 Tel: 617-573-0100





MAY 0 8 2001

TECH CENTER 1600/2900

Atty. Docket No.:

3564/1010

Group:

Examiner:

PATENT

1642

Tran, M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Sedivy et al.

U.S. Serial No.: 09/654,281

Filed:

09/01/2000

Entitled:

Kinase Inhibitors and Methods of Use

in Screening Assays and Modulation

of Cell Proliferation and Growth

BOX: SEQUENCE

Commissioner for Patents and Trademarks

Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

A corrected sequence listing is submitted in response to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures mailed by the PTO on April 3, 2001.

No amendment of the specification is needed.

Applicants, in compliance with 37 C.F.R. 1.821(f), hereby state that the information recorded in computer readable form submitted herewith is identical to the written sequence listing. Applicants, in compliance with 37 C.F.R. 1.821(g), further state that no new matter is added.

Date:

Respectfully submitted,

Name: Kathleen M. Williams Registration No.: 34,380 Palmer & Dodge LLP One Beacon Street

Boston, MA 02108 Tel: 617-573-0100

61	P E Notice	to Comply	
MAY	0 t 5001 2		

Application No.	Applicant(s)	
09/654281	SEDIVY ET AL	
Examiner	Art Unit	Attorney Docket #
MAU TRAN, PH.D.	1642	3564/1010

TICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS NEW AMENO ACID SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):	
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).	
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).	
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	/or
5. The computer readable form that has been filed with this application has been found to be damage and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute compute readable form must be submitted as required by 37 C.F.R. 1.825(d).	d r
☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
7. Other:	
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its en into the specification.	try
	ere) or
For questions regarding compliance to these requirements, please contact:	

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY